PMGC HOLDINGS INC. Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest
PMGC HOLDINGS INC. (ELAB) reported Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest of $7.76 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity · last filed 2026-03-30
- PMGC HOLDINGS INC. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2025 was $7.76M, a 24.18% increase from fiscal 2024.
- PMGC HOLDINGS INC. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2024 was $6.25M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 12 month |
|---|---|
| 2025-12-31 | $7.76M 10-K · filed 2026-03-30 |
| 2024-12-31 | $6.25M 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B |